Literature DB >> 9756330

The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.

T Town1, D Paris, D Fallin, R Duara, W Barker, M Gold, F Crawford, M Mullan.   

Abstract

The epsilon4 allele of the apolipoprotein E gene (APOE) has repeatedly been associated with increased risk for Alzheimer's disease (AD). Bullido and colleagues recently identified a polymorphism in the promoter region of the APOE gene (-491A/T) and found that -491A homozygosity predicted AD independently of APOE epsilon4. Since the -491A/T polymorphism and the known APOE polymorphism must be in tight linkage disequilibrium, and the later polymorphism is know to be associated with the disease, we wished to determine to what extent this linkage disequilibrium explained the -491A/T polymorphism association with Alzheimer's disease. We genotyped a community-based control sample (n = 132) and a clinic-based Alzheimer's disease sample (n = 190) for the known APOE and -491A/T polymorphisms, and find that, while the -491A/T polymorphism confers some independent risk for AD, linkage disequilibrium between the known APOE and -491A/T polymorphic sites explains most of the -491A association. Furthermore, when considering the known APOE and -491A/T polymorphisms alone, APOE epsilon4 status is the best predictor of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756330     DOI: 10.1016/s0304-3940(98)00567-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  A comprehensive genetic association study of Alzheimer disease in African Americans.

Authors:  Mark W Logue; Matthew Schu; Badri N Vardarajan; Jacki Buros; Robert C Green; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Rhonna Shatz; Amy Borenstein; L Adrienne Cupples; Kathryn L Lunetta; M Daniele Fallin; Clinton T Baldwin; Lindsay A Farrer
Journal:  Arch Neurol       Date:  2011-12

2.  Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association.

Authors:  Chang-En Yu; Howard Seltman; Elaine R Peskind; Nichole Galloway; Peter X Zhou; Elisabeth Rosenthal; Ellen M Wijsman; Debby W Tsuang; Bernie Devlin; Gerard D Schellenberg
Journal:  Genomics       Date:  2007-04-16       Impact factor: 5.736

3.  ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population.

Authors:  Anna Juhász; András Palotás; Zoltán Janka; Agnes Rimanóczy; Miklós Palotás; Nikoletta Bódi; Krisztina Boda; Marianna Zana; Gábor Vincze; János Kálmán
Journal:  Neurochem Res       Date:  2005-05       Impact factor: 3.996

4.  Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism.

Authors:  S M Fullerton; A G Clark; K M Weiss; D A Nickerson; S L Taylor; J H Stengârd; V Salomaa; E Vartiainen; M Perola; E Boerwinkle; C F Sing
Journal:  Am J Hum Genet       Date:  2000-09-13       Impact factor: 11.025

5.  The complex interaction between APOE promoter and AD: an Italian case-control study.

Authors:  Alessandra Bizzarro; Davide Seripa; Adele Acciarri; Maria Giovanna Matera; Alberto Pilotto; Francesco Danilo Tiziano; Christina Brahe; Carlo Masullo
Journal:  Eur J Hum Genet       Date:  2009-01-28       Impact factor: 4.246

6.  Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease.

Authors:  Kristin K Nicodemus; Judith E Stenger; Donald E Schmechel; Kathleen A Welsh-Bohmer; Ann M Saunders; Allen D Roses; John R Gilbert; Jeffery M Vance; Jonathan L Haines; Margaret A Pericak-Vance; Eden R Martin
Journal:  Neurogenetics       Date:  2004-09-29       Impact factor: 2.660

7.  Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Authors:  Romain Simon; Marion Girod; Catherine Fonbonne; Arnaud Salvador; Yohann Clément; Pierre Lantéri; Philippe Amouyel; Jean Charles Lambert; Jérôme Lemoine
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

8.  The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.

Authors:  J-C Lambert; N Coyle; C Lendon
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

9.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.

Authors:  Lynn M Bekris; Steven P Millard; Nichole M Galloway; Simona Vuletic; John J Albers; Ge Li; Douglas R Galasko; Charles DeCarli; Martin R Farlow; Chris M Clark; Joseph F Quinn; Jeffrey A Kaye; Gerard D Schellenberg; Debby Tsuang; Elaine R Peskind; Chang-En Yu
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

10.  APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure.

Authors:  Lynn M Bekris; Nichole M Galloway; Thomas J Montine; Gerard D Schellenberg; Chang-En Yu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.